FDA accepts for priority review biologics license application for evinacumab as a treatment for patients with homozygous familial hypercholesterolaemia

Application for this agent that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3) is for use as an adjunct to other lipid-lowering therapies in patients with this ultra-rare inherited disease. An accelerated assessment is already underway in the EU.


Biospace Inc.